Skip to main content Accessibility help
  • Cited by 2
  • Print publication year: 2011
  • Online publication date: August 2011

23 - Movement disorders in neurometabolic diseases

Related content

Powered by UNSILO


1. Jinnah HA, Visser JE, Harris JC et al. Delineation of the motor disorder of Lesch–Nyhan disease. Brain 2006 May; 129(Pt 5): 1201–17.
2. Roze E, Paschke E, Lopez N et al. Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 2005; 20(10): 1366–9.
3. Gitiaux C, Roze E, Kinugawa K et al. Spectrum of movement disorders associated with glutaric aciduria type 1: a study of 16 patients. Mov Disord 2008; 23(16): 2392–7.
4. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’s disease. Lancet 2007; 369(9559): 397–408.
5. Machado A, Chien HF, Deguti MM et al. Neurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord 2006; 21(12): 2192–6.
6. Sinha S, Taly AB, Ravishankar S et al. Wilson’s disease: cranial MRI observations and clinical correlation. Neuroradiology 2006; 48(9): 613–21.
7. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet. 2009; 46(2): 73–80.
8. Hayflick SJ. Unraveling the Hallervorden–Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name. Curr Opin Pediatr 2003; 15(6): 572–7.
9. Pellecchia MT, Valente EM, Cif L et al. The diverse phenotype and genotype of pantothenate kinase-associated neurodegeneration. Neurology 2005; 64(10): 1810–2.
10. Hartig MB, Hortnagel K, Garavaglia B et al. Genotypic and phenotypic spectrum of PANK2 mutations in patients with neurodegeneration with brain iron accumulation. Ann Neurol 2006; 59(2): 248–56.
11. Freeman K, Gregory A, Turner A, Blasco P, Hogarth P, Hayflick S. Intellectual and adaptive behaviour functioning in pantothenate kinase-associated neurodegeneration. J Intellect Disabil Res 2007; 51(Pt 6): 417–26.
12. Kurian MA, Morgan NV, MacPherson L et al. Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 2008; 70(18): 1623–9.
13. McNeill A, Birchall D, Hayflick SJ et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70(18): 1614–9.
14. Gregory A, Westaway SK, Holm IE et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology 2008; 71(18): 1402–9.
15. Paisan-Ruiz C, Bhatia KP, Li A et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol 2009; 65(1): 19–23.
16. Chinnery PF, Crompton DE, Birchall D et al. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain 2007; 130(Pt 1): 110–9.
17. McNeill A, Pandolfo M, Kuhn J, Shang H, Miyajima H. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008; 60(4): 200–5.
18. Aamodt AH, Stovner LJ, Thorstensen K, Lydersen S, White LR, Aasly JO. Prevalence of haemochromatosis gene mutations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78(3): 315–7.
19. Dekker MC, Giesbergen PC, Njajou OT et al. Mutations in the hemochromatosis gene (HFE), Parkinson’s disease and parkinsonism. Neurosci Lett 2003; 348(2): 117–9.
20. Demarquay G, Setiey A, Morel Y, Trepo C, Chazot G, Broussolle E. Clinical report of three patients with hereditary hemochromatosis and movement disorders. Mov Disord 2000; 15(6): 1204–9.
21. Pearl PL, Capp PK, Novotny EJ, Gibson KM. Inherited disorders of neurotransmitters in children and adults. Clin Biochem 2005; 38(12): 1051–8.
22. Manegold C, Hoffmann GF, Degen I et al. Aromatic l-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up. J Inherit Metab Dis 2009; 32(3): 371–80.
23. Clot F, Grabli D, Cazeneuve C et al. Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with dopa-responsive dystonia. Brain 2009; 132(Pt 7): 1753–63.
24. Trender-Gerhard I, Sweeney MG et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009; 80(8): 839–45.
25. Ozand PT, Gascon GG, Al Essa M et al. Biotin-responsive basal ganglia disease: a novel entity. Brain 1998; 121(Pt 7): 1267–79.
26. Bindoff LA, Birch-Machin MA, Farnsworth L, Gardner-Medwin D, Lindsay JG, Turnbull DM. Familial intermittent ataxia due to a defect of the E1 component of pyruvate dehydrogenase complex. J Neurol Sci 1989; 93(2–3): 311–8.
27. Head RA, de Goede CG, Newton RW et al. Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Dev Med Child Neurol 2004; 46(10): 710–2.
28. Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain Dev 2009; 31(7): 545–52.
29. Schneider SA, Paisan-Ruiz C, Garcia-Gorostiaga I et al. GLUT1 gene mutations cause sporadic paroxysmal exercise-induced dyskinesias. Mov Disord 2009; 24(11): 1684–8.
30. Suls A, Dedeken P, Goffin K et al. Paroxysmal exercise-induced dyskinesia and epilepsy is due to mutations in SLC2A1, encoding the glucose transporter GLUT1. Brain 2008; 131(Pt 7): 1831–44.
31. Macaya A, Munell F, Burke RE, De Vivo DC. Disorders of movement in Leigh syndrome. Neuropediatrics 1993; 24(2): 60–7.
32. Yamamoto M, Ujike H, Wada K, Tsuji T. Cerebrospinal fluid lactate and pyruvate concentrations in patients with Parkinson’s disease and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS). J Neurol Neurosurg Psychiatry 1997; 62(3): 290.
33. Luoma PT, Eerola J, Ahola S et al. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 2007; 69(11): 1152–9.
34. Oates CE, Bosch EP, Hart MN. Movement disorders associated with chronic GM2 gangliosidosis. Case report and review of the literature. Eur Neurol 1986; 25(2): 154–9.
35. Nardocci N, Bertagnolio B, Rumi V, Angelini L. Progressive dystonia symptomatic of juvenile GM2 gangliosidosis. Mov Disord 1992; 7(1): 64–7.
36. Sevin M, Lesca G, Baumann N et al. The adult form of Niemann–Pick disease type C. Brain 2007; 130(Pt 1): 120–33.
37. Berkovic SF, Carpenter S, Andermann F, Andermann E, Wolfe LS. Kufs’ disease: a critical reappraisal. Brain 1988; 111(Pt 1): 27–62.
38. Nijssen PC, Brusse E, Leyten AC, Martin JJ, Teepen JL, Roos RA. Autosomal dominant adult neuronal ceroid lipofuscinosis: parkinsonism due to both striatal and nigral dysfunction. Mov Disord 2002; 17(3): 482–7.
39. Federico A, Battistini S, Ciacci G et al. Cherry-red spot myoclonus syndrome (type I sialidosis). Dev Neurosci 1991; 13(4–5): 320–6.
40. Neumann J, Bras J, Deas E et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease. Brain 2009; 132(Pt 7): 1783–94.
41. Ceballos-Picot I, Mockel L, Potier MC et al. Hypoxanthine-guanine phosphoribosyl transferase regulates early developmental programming of dopamine neurons: implications for Lesch–Nyhan disease pathogenesis. Hum Mol Genet 2009 1; 18(13): 2317–27.
42. Schretlen DJ, Ward J, Meyer SM et al. Behavioral aspects of Lesch–Nyhan disease and its variants. Dev Med Child Neurol 2005; 47(10): 673–7.
43. Adam OR, Jankovic J. Treatment of dystonia. Parkinsonism Relat Disord 2007; 13(Suppl 3): S362–8.
44. Vidailhet M, Vercueil L, Houeto JL et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med 2005; 352(5): 459–67.
45. Kupsch A, Benecke R, Muller J et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 2006; 355(19): 1978–90.
46. Vidailhet M, Yelnik J, Lagrange C et al. Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study. Lancet Neurol 2009; 8(8): 709–17.
47. Mikati MA, Yehya A, Darwish H, Karam P, Comair Y. Deep brain stimulation as a mode of treatment of early onset pantothenate kinase-associated neurodegeneration. Eur J Paediatr Neurol 2009; 13(1): 61–4.
48. Roze E, Navarro S, Cornu P, Welter ML, Vidailhet M. Deep brain stimulation of the globus pallidus for generalized dystonia in GM1 Type 3 gangliosidosis: technical case report. Neurosurgery 2006; 59(6): E1340; discussion E.
49. Aniello MS, Martino D, Petruzzella V et al. Bilateral striatal necrosis, dystonia and multiple mitochondrial DNA deletions: case study and effect of deep brain stimulation. Mov Disord 2008; 23(1): 114–8.
50. Cif L, Biolsi B, Gavarini S, et al. Antero-ventral internal pallidum stimulation improves behavioral disorders in Lesch–Nyhan disease. Mov Disord 2007; 22(14): 2126–9.